Do prescription stimulants increase risk of Parkinson’s disease among adults with attention-deficit hyperactivity disorder? A retrospective cohort study
Family Practice · 2024
DOI: 10.1093/fampra/cmac153 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Family Practice, 2024. Verfasst von Hailey M Kindt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Penn State Hershey Medical Center, College of Medicine, Hershey, PA, United States. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Parkinson Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background
Parkinson’s disease (PD) is a common neurodegenerative disorder in older adults that is associated with neuroinflammation, oxidative stress, and characterized by loss of dopaminergic cells. Illicit stimulants increase oxidative stress and are associated with increased risk of PD. Prescription stimulants are similar in mechanism to illicit stimulants, yet their influence on PD is not well described. This study aims to determine if prescription stimulants influence risk of PD among older adults with attention-deficit and hyperactivity disorder (ADHD).
Methods
We implemented a retrospective observational cohort design utilizing the TriNetX database which sources from the electronic health records of 57 healthcare organizations. Inclusion criteria were ADHD diagnosis and age ≥50. Those exposed to stimulants and the unexposed controls were matched based on demographics and known risk factors for PD. The outcome of interest was the incidence of PD over a 30-year follow-up period. We utilized TriNetX software for hazard ratio (HR) analysis.
Results
Among the 59,471 individuals treated with prescription stimulants 131 of them developed PD, and there were 272 individuals who developed PD that were not prescribed stimulants. This analysis yielded a HR of 0.419 (HR = 0.419 [95% CI 0.34, 0.516], P = 0.0013).
Conclusion
Illicit stimulants are associated with increased risk of PD, but this study suggests prescribed stimulants may not impart that same risk. The reduced risk in this cohort may be due to protection from illicit substance use and oxidative stress, however additional study exploring the relationship between prescription stimulants and PD is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Penn State Hershey Medical Center, College of Medicine, Hershey, PA, United States.
- Penn State Hershey Medical Center, Department of Family and Community Medicine, Hershey, PA, United States.
- University of Pittsburgh School of Medicine, Department of Family Medicine, Pittsburgh, PA, United States.
ORCID-Profile: Hailey M Kindt, Wen-Jan Tuan, Curtis W Bone
Zitieren
APA
Kindt, H. M., Tuan, W. J., & Bone, C. W. (2024). Do prescription stimulants increase risk of Parkinson’s disease among adults with attention-deficit hyperactivity disorder? A retrospective cohort study. Family Practice. https://doi.org/10.1093/fampra/cmac153
Vancouver
Kindt HM, Tuan WJ, Bone CW. Do prescription stimulants increase risk of Parkinson’s disease among adults with attention-deficit hyperactivity disorder? A retrospective cohort study. Family Practice. 2024. doi:10.1093/fampra/cmac153
BibTeX
@article{Kindt2024,
author = {Kindt, Hailey M and Tuan, Wen-Jan and Bone, Curtis W},
title = {Do prescription stimulants increase risk of Parkinson’s disease among adults with attention-deficit hyperactivity disorder? A retrospective cohort study},
journal = {Family Practice},
year = {2024},
doi = {10.1093/fampra/cmac153}
}
EUVIMED